US › Healthcare

Agenus Inc (AGEN)

US · Healthcare · Biotechnology

$8.30+6.14%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$33.7M
Revenue YoY
+40.2%
Net profit
$39.2M
Profit YoY
+255.3%
EPS
$-0.03
EPS estimate
$1.80
Net margin
116.3%

EPS came in at -0.03 against a street estimate of 1.80 — a miss of 101.7%.

Key statistics

Market cap
$312.3M
P/E
3.7
Forward P/E
3.4
P/B
218.61
Book value
$-5.74
EPS (TTM)
$2.05
52-week high
$8.70
52-week low
$2.71
50-day MA
$4.04
200-day MA
$3.78
Beta
1.55

Analyst view

Analysts rate Agenus Inc a buy (2 buy, 3 hold, 0 sell out of 5) with an average price target of $22.00.

Shareholding

Insiders
6.73%
Institutions
37.11%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC3.22%
Vanguard Portfolio Management, LLC2.67%
Siren, L.L.C.2.38%
Marshall Wace Asset Management Ltd1.54%
BlackRock Inc1.22%
Geode Capital Management, LLC0.78%
Morgan Stanley - Brokerage Accounts0.66%
Renaissance Technologies Corp0.64%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Agenus Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.